Insider Selling: Milestone Pharmaceuticals (NASDAQ:MIST) Insider Sells $124,273.12 in Stock

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) insider Lorenz Muller sold 53,566 shares of the company’s stock in a transaction on Monday, December 15th. The stock was sold at an average price of $2.32, for a total transaction of $124,273.12. Following the completion of the sale, the insider owned 196,486 shares of the company’s stock, valued at approximately $455,847.52. The trade was a 21.42% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Lorenz Muller also recently made the following trade(s):

• On Monday, January 26th, Lorenz Muller sold 11,180 shares of Milestone Pharmaceuticals stock. The shares were sold at an average price of $1.93, for a total value of $21,577.40.

Milestone Pharmaceuticals Stock Performance

NASDAQ MIST traded down $0.07 during trading on Wednesday, hitting $1.94. 1,697,941 shares of the company’s stock traded hands, compared to its average volume of 3,110,069. The stock has a market capitalization of $165.23 million, a price-to-earnings ratio of -2.37 and a beta of 0.44. The business has a 50 day moving average of $2.23 and a 200-day moving average of $1.96. Milestone Pharmaceuticals Inc. has a 12-month low of $0.63 and a 12-month high of $3.06. The company has a debt-to-equity ratio of 2.74, a quick ratio of 8.24 and a current ratio of 8.24.

Milestone Pharmaceuticals (NASDAQ:MIST) last posted its earnings results on Wednesday, November 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.05. As a group, equities research analysts anticipate that Milestone Pharmaceuticals Inc. will post -0.62 earnings per share for the current fiscal year.

More Milestone Pharmaceuticals News

Here are the key news stories impacting Milestone Pharmaceuticals this week:

• Positive Sentiment: Milestone launched CARDAMYST nasal spray for U.S. pharmacy availability — a commercial milestone that could begin to drive product revenue and awareness. Milestone Launches CARDAMYST Nasal Spray in U.S. Pharmacies
• Positive Sentiment: Analyst optimism rose after Zacks upgraded MIST from “Hold” to a “Strong Buy” (Zacks Rank #1), which may attract buyers and short‑term momentum flows. All You Need to Know About Milestone Pharmaceuticals (MIST) Rating Upgrade to Strong Buy
• Neutral Sentiment: Trading context: shares are trading below the 50‑day moving average and volume is below the stock’s average, which can mute a sustained bounce despite the product launch and upgrade.
• Negative Sentiment: CEO Joseph Oliveto completed sizeable stock sales: 133,054 shares on Dec. 15 at ~$2.32 and 34,523 shares on Jan. 26 at ~$1.93 — material reductions disclosed to the SEC that may worry investors about insider confidence or trigger selling pressure. SEC Form 4 – Joseph Oliveto
• Negative Sentiment: Other insiders (David Bharucha and Lorenz Muller) also sold large blocks on both Dec. 15 (~58k and ~53.6k shares respectively) and Jan. 26 (~12.2k and ~11.2k shares respectively), representing substantial percentage reductions in their holdings. These clustered insider sales intensify negative sentiment. SEC Form 4 – David Bharucha SEC Form 4 – Lorenz Muller
• Negative Sentiment: COO Jeffrey Nelson similarly sold significant shares on Dec. 15 and Jan. 26 (including ~58k on Dec. 15), cutting his stake materially — another factor pressuring sentiment. SEC Form 4 – Jeffrey Edward Nelson

Wall Street Analyst Weigh In

Several equities research analysts have commented on MIST shares. Wall Street Zen downgraded Milestone Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, January 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a research note on Monday, December 29th. Wells Fargo & Company lifted their price target on shares of Milestone Pharmaceuticals from $4.00 to $8.00 and gave the company an “overweight” rating in a report on Tuesday, December 16th. Zacks Research upgraded shares of Milestone Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday. Finally, TD Cowen upgraded Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, December 15th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Milestone Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $8.00.

Institutional Trading of Milestone Pharmaceuticals

Large investors have recently made changes to their positions in the stock. Simplify Asset Management Inc. increased its position in shares of Milestone Pharmaceuticals by 186.2% during the third quarter. Simplify Asset Management Inc. now owns 2,832,974 shares of the company’s stock worth $5,666,000 after acquiring an additional 1,842,974 shares during the period. Valeo Financial Advisors LLC boosted its position in Milestone Pharmaceuticals by 553.5% during the second quarter. Valeo Financial Advisors LLC now owns 130,699 shares of the company’s stock valued at $254,000 after purchasing an additional 110,699 shares in the last quarter. Bay Rivers Group grew its position in shares of Milestone Pharmaceuticals by 72.9% in the 4th quarter. Bay Rivers Group now owns 28,861 shares of the company’s stock worth $58,000 after buying an additional 12,170 shares during the last quarter. Boxer Capital Management LLC acquired a new position in shares of Milestone Pharmaceuticals during the third quarter worth $1,333,000. Finally, Aptus Capital Advisors LLC acquired a new stake in Milestone Pharmaceuticals in the third quarter worth about $420,000. 86.18% of the stock is owned by hedge funds and other institutional investors.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.